Canopy Growth Vs. Tilray Brands: Which Cannabis Stock Is …

Key Financial Metrics

CGC – Canopy Growth

$0.74

+2.91% (+$0.02)

TLRY – Tilray Brands

$3.21

+2.23% (+$0.07)

Market Cap

$302M

52wk Range

$0.69 – $2.38

Gross Margin

18.25%

P/E Ratio

-1.58

EPS (TTM)

-$0.45

Market Cap

$464M

52wk Range

$3.07 – $16.88

Gross Margin

26.82%

P/E Ratio

-2.25

EPS (TTM)

-$1.40

CGC – Canopy Growth

$0.74

+2.91% (+$0.02)

Market Cap

$302M

52wk Range

$0.69 – $2.38

Gross Margin

18.25%

P/E Ratio

-1.58

EPS (TTM)

-$0.45

TLRY – Tilray Brands

$3.21

+2.23% (+$0.07)

Market Cap

$464M

52wk Range

$3.07 – $16.88

Gross Margin

26.82%

P/E Ratio

-2.25

EPS (TTM)

-$1.40

The case for Canopy Growth

In its latest annual report, filed for the fiscal year ended March 31, 2026, Canopy Growth detailed its strategy to produce cannabis-based products with a focus on quality. The company derives a significant portion of its revenue from supply contracts with all 12 Canadian provinces and territories. Customer concentration this adds a layer of risk to the business, as these contracts lack binding minimum purchase obligations. The company is also making a push into the pharmaceutical stocks category through medical distributions in Europe.

In FY 2026, revenue reached nearly $199.5 million, representing a 5.8% increase compared to the prior year. Despite this growth, the company reported a net loss of approximately $184.3 million. This resulted in a negative operating margin of 92.4%, indicating the company is losing significant money on its sales. While still deep in the red, this net loss was an improvement over the $419.3 million loss reported in the prior fiscal year.

As of its March 2026 balance sheet, the debt-to-equity ratio is roughly 0.4x. This ratio measures total debt relative to holder equity, indicating a relatively low reliance on borrowed funds. The current ratio, which compares short-term assets to short-term liabilities, is about 3.3x. Free cash flow for FY 2026 was nearly negative $48.9 million, representing the cash remaining after a business pays for its operations and equipment.

The case for Tilray Brands

Tilray Brands operates as a global lifestyle consumer products company. It maintains a large distribution segment supplying pharmaceutical products to pharmacies in Germany and over 900 beverage wholesalers in the U.S. its peer, Tilray relies on contracts with Canadian provinces for cannabis sales, which carry no minimum volume guarantees. This diversification helps buffer the company against localized price swings in the marijuana industry.

In FY 2026, Tilray reported revenue of close to $915.5 million, which was a decrease of approximately 18.8% from the previous year. The company recorded a net loss of roughly $122.6 million for the period. Its net margin was approximately negative 13.4%, a much narrower loss than the negative 266.3% net margin seen in FY 2025. This suggests the company is moving closer to breaking even than in previous years.

As of its May 2026 balance sheet, Tilray has a debt-to-equity ratio of approximately 0.2x. The current ratio is nearly 2.2x, showing the company has over twice as many short-term assets as it has immediate debts. Free cash flow for FY 2026 was close to negative $102.1 million. This figure indicates the company is still consuming cash to maintain and grow its global operations across its cannabis and beverage segments.

Risk profile comparison

Canopy Growth faces material risks including a recently identified material weakness in its internal financial controls. This led to a restatement of prior financial data and could harm investor trust in its reporting. The company also deals with regulatory uncertainty regarding its Canopy USA expansion and potential delisting threats. Its history of net losses since 2019 raises doubts about its ability to continue operating if cost-cutting does not succeed in a saturated Canadian market.

Tilray Brands must navigate high regulatory hurdles and licensing requirements across dozens of international jurisdictions. It faces intense competition from rivals TerrAscend (TSNDF +6.82%) and the illicit market, which can squeeze operating margins. The company relies heavily on an acquisition-based strategy, including brands BrewDog, which can lead to integration challenges. Fluctuating foreign currency rates and a reliance on third-party distributors further complicate its financial performance.

Valuation comparison

Tilray appears cheaper on a sales basis with a much lower P/S ratio, which measures a company’s market value relative to its sales over the past twelve months.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

Neither of these is an easy pick right now, and anyone considering either stock should understand that the cannabis industry is still working through a difficult period. U.S. federal legalization keeps getting delayed, pricing pressure is intense in mature markets, and most cannabis companies are still burning cash years after their initial promise.

That said, if I had to choose, I’d go with Tilray. In Q1 fiscal 2027, it posted record revenue of $257 million, up 23% year over year, with gross profit growing even faster. Its acquisition of BrewDog turned profitable in the quarter and is now self-financing, a meaningful sign that Tilray’s diversification into beverages is working.

Canopy Growth is making progress, too. In Q1 fiscal 2027, revenue grew 13% across every business segment, margins improved, and losses narrowed significantly. Management expects to reach positive adjusted EBITDA by year-end.

For long-term investors, the question is not just whether these companies reach profitability, but whether the cannabis market itself stabilizes enough to reward the patience required to hold either stock. Right now, Tilray’s larger scale, diversified revenue across cannabis, beverages, and international markets, and a clearer path to profitability make it the more comfortable of two difficult choices.

Read Next

Oct 13, 2026 •By Jeremy Bowman

How to Buy Canopy Growth Stock (CGC) in 2026

Oct 10, 2026 •By Sarah Sidlow

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?

Oct 6, 2026 •By David Jagielski, CPA

Can Canopy Growth Survive Another 5 Years?

Sep 30, 2026 •By Jeff Siegel

Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?

Sep 23, 2026 •By Reuben Gregg Brewer

Canopy Growth Is Eyeing Another Reverse Stock Split. Will It Be Enough to Light a Fire Beneath the Beaten-Down Pot Stock?

Oct 15, 2026 •By Sara Appino

GE Aerospace vs. Lockheed Martin: Which Stock Is a Better Buy in 2026?

About the Author

Sara Appino is a contributing writer at The Motley Fool. Previously she held roles at McGraw-Hill Education, Sourcebooks, and The Field Museum of Natural History. A graduate of the University of Chicago and Northwestern University’s Medill School of Journalism, Sara also managed a surf and yoga retreat in Costa Rica for nearly a decade and helped launch a nonprofit English language program in her community there.

TMFSaraA

Stocks Mentioned

Motley Fool Stock Advisor’s Latest Pick

Get Access

—% Avg Return

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.